Review



mpc  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC mpc
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    Mpc, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 258 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/MPC-11/pmc13266118-123-0-5
    Average 96 stars, based on 258 article reviews
    mpc - by Bioz Stars, 2026-11
    96/100 stars

    Images

    1) Product Images from "Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition"

    Article Title: Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition

    Journal: Molecular Therapy Oncology

    doi: 10.1016/j.omton.2026.201226

    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS treated MPC-11 tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    Figure Legend Snippet: Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS treated MPC-11 tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.

    Techniques Used: Clinical Proteomics, Saline

    Related Articles

    other:

    Article Title: Elevation of JAML Promotes Diabetic Kidney Disease by Modulating Podocyte Lipid Metabolism.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Goat polyclonal Secondary Antibody to Guinea pig IgG - H&L (Alexa Fluor 594) (1:500) Abcam Cat# ab150188; RRID: AB_2782993 Goat polyclonal Secondary Antibody to Guinea pig IgG - H&L (Alexa Fluor 488) (1:500) Abcam Cat# ab150185; RRID: AB_2736871 Donkey polyclonal Secondary Antibody to Goat IgG - H&L (Alexa Fluor 594) (1:500) Abcam Cat#ab150136; RRID: AB_2782994 Normal rabbit IgG Cell signaling technology Cat# 2729S; RRID: AB_103106 Normal mouse IgG Santa Cruz biotechnology Cat# sc2025; RRID: AB_737182 Chemicals, Peptides, and Recombinant Proteins Streptozocin Sigma-Aldrich Cat# S0130 High-fat diet (60 kcal% from fat) Research Diets Cat# D12492 Adriamycin Shenzhen Main Luck pharmaceuticals Inc. H44024359 Recombinant murine IFN-g Peprotech Cat# 315-05 Penicillin/Streptomycin Solarbio Cat# P1400 Oxidized low density lipoprotein, human Yiyuan biotechnologies Cat# YB-002 Palmitic acid Sigma-Aldrich Cat# P5585 Cholesterol Sigma-Aldrich Cat# C3045 Mannitol Sigma-Aldrich Cat# M4125 Dynabeads M-450 Tosylactivated Invitrogen Cat# 14013 Oil Red O Sigma-Aldrich Cat# O0625 Nile Red Solarbio Cat# N8440 D- (+) Glucose Sigma-Aldrich Cat# G8270 Phosphatase Inhibitor Cocktail APExBIO Technology LLC Cat# K1015 Proteinase E Sigma-Aldrich Cat# P6911 Collagenase A Roche Cat# 10103586001 Deoxyribonuclease Sigma-Aldrich Cat# D4527 100mM PMSF Beyotime Biotechnology Cat# ST506-2 Hematoxylin solution Solarbio Cat# G1140 Lipofectamine 2000 transfection reagent Invitrogen Cat# 11668500 Acti-stain 555 phalloidin Cytoskeleton Cat# PHDH1 Primary Antibody Dilution Buffer Beyotime Biotechnology Cat# P0023A Critical Commercial Assays Mouse JAML/AMICA ELISA Kit Omnimabs Cat# OM625628 Human JAML/AMICA ELISA Kit Omnimabs Cat# OM625627 Periodic Acid Schiff Diastase/PAS-D Stain Kit Solarbio Cat# G1282 Immobilon Western Chemiluminescent HRP substrate Millipore Cat# WBKLS0100 In Situ Cell Death Detection Kit for TUNEL assay Roche Cat# 12156792910 Deposited Data RNA-sequencing data This paper GEO: GSE156367 Experimental Models: Cell Lines Murine: MPC A kind gift from Prof. Pin-Lan Li Department of Pharmacology, Virginia Commonwealth University N/A Rat: RMC ATCC CRL-2573 Rat: GEC Creative Bioarray (Shirley, NY, USA) N/A (Continued on next page) Cell Metabolism 32, 1–11.e1–e8, December 1, 2020 e2

    Article Title: In Vitro Resistance Selection in Shigella flexneri by Azithromycin, Ceftriaxone, Ciprofloxacin, Levofloxacin, and Moxifloxacin
    Article Snippet: table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Antimicrobial ATCC 12022 m-12022 MIC (mg/liter) MPC (mg/liter) MIC (mg/liter) MPC (mg/liter) Azithromycin 4 >64 8 >64 Ceftriaxone 0.0625 0.5 0.125 2 Ciprofloxacin 0.03125 0.25 0.25 2 Levofloxacin 0.0625 0.5 0.25 2 Moxifloxacin 0.0625 0.5 0.5 2 Open in a separate window MIC and MPC results

    Selection:

    Article Title: Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model.
    Article Snippet: As in the static selection study, the G2576T replacement was found in RMs of S. aureus 479 and S. aureus ATCC 700699 but not S. aureus 688. .. At the highest AUC24/MIC ratio (240), when linezolid concentrations were above the MPC (TMSW 0% for S. aureus 479 and 688 or 10% for S. aureus ATCC 700699), the selection of RMs did not occur. ..



    Similar Products

    mpc  (ATCC)
    96
    ATCC mpc
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    Mpc, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/MPC-11/pmc13266118-123-0-5
    Average 96 stars, based on 1 article reviews
    mpc - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    e6 1  (ATCC)
    93
    ATCC e6 1
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    E6 1, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/MPC+11+OUAr/pm42827183-255-3-4
    Average 93 stars, based on 1 article reviews
    e6 1 - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier
    mpc 11 mouse tumors  (ATCC)
    96
    ATCC mpc 11 mouse tumors
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    Mpc 11 Mouse Tumors, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/MPC-11/us12655222-489-17-40
    Average 96 stars, based on 1 article reviews
    mpc 11 mouse tumors - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    mpc11  (ATCC)
    96
    ATCC mpc11
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    Mpc11, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/MPC-11/pmc13148948-199-36-37
    Average 96 stars, based on 1 article reviews
    mpc11 - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    linear multi point constraint mpc equations  (Abaqus Inc)
    86
    Abaqus Inc linear multi point constraint mpc equations
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    Linear Multi Point Constraint Mpc Equations, supplied by Abaqus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/constraint+mpc+multi+point+subroutine/pm42151261-204-31-29
    Average 86 stars, based on 1 article reviews
    linear multi point constraint mpc equations - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    mpc  (Mesoblast Ltd)
    86
    Mesoblast Ltd mpc
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    Mpc, supplied by Mesoblast Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/mpc/pmc13176351-36-4-5
    Average 86 stars, based on 1 article reviews
    mpc - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    milk protein concentrate mpc  (Agropur Inc)
    86
    Agropur Inc milk protein concentrate mpc
    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS <t>treated</t> <t>MPC-11</t> tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.
    Milk Protein Concentrate Mpc, supplied by Agropur Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mpc/concentrate+milk+mpc+protein/pm42075077-41-0-12
    Average 86 stars, based on 1 article reviews
    milk protein concentrate mpc - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS treated MPC-11 tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.

    Journal: Molecular Therapy Oncology

    Article Title: Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition

    doi: 10.1016/j.omton.2026.201226

    Figure Lengend Snippet: Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS treated MPC-11 tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.

    Article Snippet: MPC-11 murine plasmacytoma cells (CCL-167, American Type Culture Collection, Manassas, VA) were maintained in DMEM supplemented with 10% fetal bovine serum.

    Techniques: Clinical Proteomics, Saline